MAYRA DERUPE: Open Payments
NPI 1942783410 · MISSION, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$927 in 33 payments from 10 companies in 2025. Trend: 2023 $922 · 2024 $833 · 2025 $927
Food & beverage: $927
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 13 | $311 |
| Madrigal Pharmaceuticals | 2 | $143 |
| Ardelyx, Inc. | 5 | $117 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $109 |
| Janssen Biotech, Inc. | 2 | $71 |
| Phathom Pharmaceuticals, Inc. | 3 | $43 |
| Novo Nordisk Inc | 2 | $43 |
| Ipsen Biopharmaceuticals, Inc | 2 | $42 |
| Intercept Pharmaceuticals, Inc. | 2 | $33 |
| Gilead Sciences, Inc. | 1 | $14 |
Products named: CREON, REZDIFFRA, LINZESS, IBSRELA, XIFAXAN, TREMFYA, VOQUEZNA, Wegovy.
Industry payments across TX — which companies pay providers there.
